Chronic Hepatitis News

Among the three largest Hispanic population subgroups, researchers found high levels of heterogeneity in chronic liver disease-related mortality patterns, according to a recently published study.

Patients undergoing direct-acting antiviral therapy for hepatitis C who had non-characterized liver nodules had a higher risk for hepatocellular carcinoma within a short follow-up time than other patients, according to a recently published study.

Dicerna Pharmaceuticals announced the dosing of the first volunteer in a phase 2 clinical trial of DCR-HBVS, the company’s investigational GalXCTM-based therapy for the treatment of chronic hepatitis B, according to a press release.

Lincoln Financial Group and the American Liver Foundation have joined together to raise awareness of hepatitis C in the U.S. and improve educational resources, according to a press release.

Between 2010 and 2017, the number and percentage of deceased donor organs with a transmissible infectious disease — such as hepatitis C, hepatitis B or HIV — increased in the U.S., which may likely be tied to the ongoing opioid epidemic, according to a recent report from the CDC.

Over the past 15 years, there was a 12.5% increase in the number of liver transplantations for patients with alcohol-associated liver disease, according to findings published in JAMA Internal Medicine.

Patients with complete response to hepatocellular carcinoma and underwent direct-acting antiviral therapy for hepatitis C had similar rates of cancer recurrence compared with patients who did not receive DAA therapy, according to a study published in Gastroenterology.

HepVu — an interactive online resource designed to visualize data on the U.S. hepatitis C epidemic — announced the release of new interactive maps that provide state-level estimates of HCV infections, according to a press release and online presentation.

Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

A decentralized, nurse-led model of hepatitis C care with direct-acting antivirals was significantly effective and led to high levels of sustained virologic response in a large cohort of inmates, according to a recently published study.